| Biomarker ID | 922 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation Status Of ACTL6B; AEBP1; AMID; CD8A; CRIP1; FLJ30934; FLNC; FMOD; FOXE3; GAS7; GDPD5; HS3ST2; LOC349136; NEUROG1; PLTP; PTGER2; RASGRF2; RUNX3; SIX6; SLC9A3; SPSB4; SRD5A2; SUSD3; SYT10; TMEM74 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethlated in recurrent prostate cancer : |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | recurrent prostate cancer Vs nonrecurrent cancer |
| Type of Biomarker | Prognostic |
| Cohort | 4 different sub groups of patients with prostate cancer: (i) tumor (n = 158) versus matched normal tissues (n = 34), (ii) recurrence (n = 98) versus nonrecurrence (n = 60); (iii) clinical recurrence (n = 59) versus biochemical recurrence (n = 39); and (iv) systemic recurrence (n = 23) versus local recurrence (n = 36) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Methylation27 microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ACTL6B, AEBP1, AMID, CD8A, CRIP1, FLJ30934, FLNC, FMOD, FOXE3, GAS7, GDPD5, HS3ST2, LOC349136, NEUROG1, PLTP, PTGER2, RASGRF2, RUNX3, SIX6, SLC9A3, SPSB4, SRD5A2, SUSD3, SYT10, TMEM74 |